Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 5/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595139 | 0.88 | PTGER1 (0.41) | ICMTPDE4BADRB2ADRB1ADRB3 | |
| SCHEMBL4037595 | 0.88 | ICMT (0.39) | ICMT | |
| SCHEMBL4348472 | 0.84 | PTGS2 (0.39) | ICMTIRAK4HDAC1HDAC8HDAC6 | |
| SCHEMBL3594920 | 0.80 | PTGER1 (0.41) | ICMTIRAK4PDE4BHDAC1HDAC8 | |
| SCHEMBL3592829 | 0.79 | ICMT (0.41) | ICMTIRAK4PDE4BPTGER1 | |
| SCHEMBL4354618 | 0.78 | KDM4E (0.36) | PDE4BHDAC1HDAC8HDAC6ADRB2 | |
| SCHEMBL4035309 | 0.76 | ICMT (0.51) | ICMTNR1D1 | |
| SCHEMBL4354611 | 0.73 | PTGDR2 (0.38) | PDE4BHDAC1HDAC8HDAC6ADRB2 | |
| SCHEMBL3589491 | 0.72 | NPC1 (0.44) | IRAK4PTGER1 | |
| SCHEMBL4362553 | 0.72 | PTGDR2 (0.39) | PDE4BHDAC1HDAC8HDAC6ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| EP-2041126-A1 | INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006794-A1 | INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | PTGER1, PTGER2, PTGER3 | ICMT 946/4885NR1D1 334/4885IRAK4 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.